| CARM1 is a type I protein arginine methyltransferase that catalyzes asymmetric dimethylation of arginine residues on its histone or non-histone substrates. Recent studies have proven that CARM1 is up-regulated in several types of malignant tumors and has oncogenic activity. Highly expressed CARM1 promotes tumors progression through various mechanisms, such as affecting tumor immunity, tumor metabolism and autophagy. Therefore, CARM1 has been considered as a promising anti-tumor target. Many researchers are trying to identify small molecule inhibitors specially targeting CARM1 to treat malignant tumors. Noticeably, CARM1 inhibitors have shown a good therapeutic prospect in pre-clinical research, suggesting that targeting CARM1 may provide a new strategy for tumor treatment. In this review, we will cover current advances of CRAM1 in tumor, including its molecular structure, tumor biological function, molecular mechanism, and specific CARM1 inhibitors. |
